269 561

Cited 78 times in

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

DC Field Value Language
dc.contributor.author조상래-
dc.date.accessioned2015-04-24T17:17:37Z-
dc.date.available2015-04-24T17:17:37Z-
dc.date.issued2009-
dc.identifier.issn0305-7453-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105123-
dc.description.abstractBACKGROUND: Although previous studies have suggested that linezolid may be effective for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), the optimal dose of linezolid for intractable MDR/XDR-TB is not clear. METHODS: Twenty-four patients with intractable MDR/XDR-TB were treated with a daily 300 mg dose of linezolid as part of their anti-TB drug regimen. RESULTS: The patients were treated with linezolid for a median duration of 359 days [interquartile range (IQR) 268-443 days]. Seventeen (71%) patients received 300 mg of linezolid once daily from the beginning of treatment for a median duration of 289 days (IQR 233-405 days). Of these patients, four developed peripheral neuropathy, one of whom discontinued linezolid. In seven (29%) patients, 600 mg/day linezolid was administered initially for a median duration of 104 days (IQR 26-145 days) followed by 300 mg/day linezolid for a median duration of 348 days (IQR 298-427 days). In five of these seven patients, the reason for changing from 600 to 300 mg/day was due to side effects of 600 mg/day linezolid (peripheral neuropathy in four patients and leucopenia in one patient). After reducing the dose to 300 mg/day, linezolid could be continued in six of the seven patients. Negative sputum conversion was achieved in 22 (92%) patients after a median of 89 days from the start of linezolid treatment (IQR 48-160 days). CONCLUSIONS: A daily 300 mg dose of linezolid may be useful for increasing the chances of culture conversion in the treatment of patients with intractable MDR/XDR-TB and might have fewer side effects, especially neurotoxicity, compared with a daily 600 mg dose of linezolid therapy. The present results encourage further research into the use of a 300 mg dose of linezolid for MDR/XDR-TB patients-
dc.description.statementOfResponsibilityopen-
dc.format.extent388~391-
dc.relation.isPartOfJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAcetamides/administration & dosage*-
dc.subject.MESHAcetamides/adverse effects-
dc.subject.MESHAcetamides/therapeutic use*-
dc.subject.MESHAdult-
dc.subject.MESHAntitubercular Agents/administration & dosage*-
dc.subject.MESHAntitubercular Agents/adverse effects-
dc.subject.MESHAntitubercular Agents/therapeutic use*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLinezolid-
dc.subject.MESHMale-
dc.subject.MESHOxazolidinones/administration & dosage*-
dc.subject.MESHOxazolidinones/adverse effects-
dc.subject.MESHOxazolidinones/therapeutic use*-
dc.subject.MESHSputum/microbiology-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTuberculosis, Multidrug-Resistant/drug therapy*-
dc.titleDaily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Microbiology (미생물학)-
dc.contributor.googleauthorWon-Jung Koh-
dc.contributor.googleauthorO. Jung Kwon-
dc.contributor.googleauthorHyesun Gwak-
dc.contributor.googleauthorJoo Won Chung-
dc.contributor.googleauthorSang-Nae Cho-
dc.contributor.googleauthorWoo Sung Kim-
dc.contributor.googleauthorTae Sun Shim-
dc.identifier.doi10.1093/jac/dkp171-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03824-
dc.relation.journalcodeJ01237-
dc.identifier.eissn1460-2091-
dc.identifier.pmid19468028-
dc.subject.keywordMDR-TB-
dc.subject.keywordXDR-TB-
dc.subject.keywordoxazolidinones-
dc.subject.keywordefficacy-
dc.subject.keywordtolerability-
dc.contributor.alternativeNameCho, Sang Nae-
dc.contributor.affiliatedAuthorCho, Sang Nae-
dc.citation.volume64-
dc.citation.number2-
dc.citation.startPage388-
dc.citation.endPage391-
dc.identifier.bibliographicCitationJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, Vol.64(2) : 388-391, 2009-
dc.identifier.rimsid56766-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.